Table 2 Demographics, clinical characteristics, and outcomes of PNC assay in 69 patients with SLE (SLE cohort)
Characteristics | Data |
|---|---|
Age, yr | |
Mean (SD) | 41.4 (13.7) |
Median (range) | 39.2 (18–76) |
Female sex, n (%) | 63 (91.3) |
Disease duration, yr, median (range) | 7.5 (0–41) |
Follow-up duration, d, median (range) | 778 (139–1792) |
Corticosteroid treatment, n (%) | 33 (47.8) |
Prednisolone equivalent, average dose last 2 mo, median (range) | 10 (1–60) mg/d |
Antimalarial treatment | 46 (66.7) |
Hydroxychloroquine, average dose last 2 mo, median (range) | 200 (46.6–400) mg/d |
Immunomodulatory treatment, n (%) | 37 (53.6) |
ACR classification criteria n (%) | |
Malar rash | 46 (67 %) |
Discoid rash | 18 (26 %) |
Photosensitivity | 42 (61 %) |
Oral ulcer | 16 (23 %) |
Arthritis | 55 (80 %) |
Serositis | 35 (51 %) |
Glomerulonephritis | 35 (51 %) |
Hematologic disorder | 38 (55 %) |
Neurologic disorder | 3 (4 %) |
Immunologic disorder | 53 (77 %) |
ANA positivity | 69 (100 %) |
Outcome of PNC assay, % CD66+PI+ PMNs | |
Mean (SD) | 7.3 (9.0) |
Median (range) | 3.4 (0.8–49.9) |